Tripelennamine citrate - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for tripelennamine citrate and what is the scope of patent protection?
Tripelennamine citrate
is the generic ingredient in one branded drug marketed by Novartis and is included in one NDA. Additional information is available in the individual branded drug profile pages.Summary for tripelennamine citrate
| US Patents: | 0 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 20 |
| DailyMed Link: | tripelennamine citrate at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for tripelennamine citrate
US Patents and Regulatory Information for tripelennamine citrate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | PBZ | tripelennamine citrate | ELIXIR;ORAL | 005914-004 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
